A Two-Phase Clinical Study of the Minerva AURORA Ablation System

Menorrhagia Due to Benign Causes Clinical Trial

Official title:

A Two-Phase Clinical Study of the Minerva AURORA Ablation System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02035332
• Other study ID #: CIP0001
• Status: Completed
• Phase: N/A
• First received: January 10, 2014
• Last updated: September 23, 2015
• Start date: May 2011
• Est. completion date: February 2015

Study information

• Verified date: September 2015
• Source: Minerva Surgical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hungary: Scientific and Medical Research Council Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the use of the Aurora Ablation System in reducing menstrual blood loss at 12 months post-treatment. The occurrence of adverse events will be assessed along with an assessment of the reduction of uterine bleeding as measured by a pictorial blood loss assessment chart (PBLAC) or menstrual diary.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: February 2015
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Refractory menorrhagia with no definable organic cause (abnormal uterine bleeding)

2. Female subject from age 35 to 50 years

3. Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)

4. A minimum PBLAC score of >150 for 3 months prior to study enrollment; OR, A minimum PBLAC score >150 for one month for women who either

1. had at least 3 prior months documented failed medical therapy; or

2. had a contraindication to medical therapy; or

3. refused medical therapy

5. Premenopausal at enrollment as determined by FSH measurement = 40 IU/ml

6. Not pregnant and no desire to conceive at any time

7. Patient agrees not to use hormonal contraception or any other medical intervention for bleeding during the study

8. Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC

9. Subject agrees to follow-up exams and data collection, including ability to accurately use menstrual diaries

10. Subject who is literate or demonstrates an understanding on how to use menstrual diaries

Exclusion Criteria:

1. Pregnancy or subject with a desire to conceive

2. Complex endometrial hyperplasia as confirmed by histology

3. Presence of active endometritis

4. Active pelvic inflammatory disease

5. Active sexually transmitted disease (STD)

6. Presence of bacteremia, sepsis, or other active systemic infection

7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure

8. Known/suspected gynecological malignancy within the past 5 years

9. Known clotting defects or bleeding disorders

10. Untreated/unevaluated cervical dysplasia

11. Known/suspected abdominal/pelvic cancer

12. Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., transmural myomectomy or classical cesarean section)

13. Previous endometrial ablation procedure

14. Currently on medications that could thin the myometrial muscle, such as long-term steroid use

15. Currently on anticoagulants

16. Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:

1. Septate or bicornuate uterus or other congenital malformation of the uterine cavity

2. Pedunculated or submucosal myomas distorting the uterine cavity

3. Polyps likely to be the cause of the subject's menorrhagia

4. Intramural or subserosal myomas that distort the uterine cavity

17. Presence of an intrauterine device (IUD)

18. Subject currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation.

19. Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject

20. Any subject who is participating in any other research of an investigational drug or device that has not yet completed the primary endpoint evaluation.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Menorrhagia
• Menorrhagia Due to Benign Causes

Intervention

Device:
• Aurora Endometrial Ablation System
Ablation of the endometrial lining of the uterus using the Aurora System

Locations

Country	Name	City	State
Hungary	Szt Imre Hospital	Budapest
Hungary	Kenézy Hospital	Debrecen	Hajdú-Bihar
Hungary	University of Szeged	Szeged	Csongrad

Sponsors (1)

Lead Sponsor	Collaborator
Minerva Surgical, Inc.

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in Menstrual Blood Loss to Normal Levels at 12-months	Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of <=75. A score of 0 represents no bleeding.	12 Months	No
Secondary	Procedure Time	Procedure time defined as time from insertion of the Disposable Handpiece to the time of removal.	Day of procedure	No